Skip to main content
Premium Trial:

Request an Annual Quote

DNASTAR, 454 Life Sciences, Illumina, Sanger, Tripos

Premium
DNASTAR has introduced its SeqMan Genome Assembler software, which enables researchers to assemble fragment data sequenced using next-generation instruments made by 454 Life Sciences, Illumina, and traditional Sanger technologies.
 
SeqMan Genome Assembler integrates with DNASTAR’s existing Lasergene suite of sequence-analysis software, allowing users to assemble and analyze sequences on Windows and Macintosh platforms.
 
The software permits users to work with multiple platforms in the same project and allows them to perform alignments and SNP discoveries, among other analyses, on de novo or templated assemblies or with resequencing projects, the company said.
 

 
Tripos has released its SYBYL 8.0 discovery research product. The upgrade has been designed to optimize processes and workflow, the company said in a statement.
 
SYBYL 8.0 contains tools designed to optimize structures as well as visualize and compare molecular models and structures. Other parts allow enhanced visualization capability and searching capabilities for lead identification tailored to accelerate and simplify the discovery process.
 
SYBYL 8.0 “enables data to be associated directly with visualized structures, and among many other benefits, includes capability for ligand- and receptor-based designs," according to Tripos development manager John Begemann.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more